484 related articles for article (PubMed ID: 33053650)
1. Toward Drug-Like Multispecific Antibodies by Design.
Sawant MS; Streu CN; Wu L; Tessier PM
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053650
[TBL] [Abstract][Full Text] [Related]
2. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
Gu J; Ghayur T
Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
[TBL] [Abstract][Full Text] [Related]
3. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies.
Harms BD; Kearns JD; Iadevaia S; Lugovskoy AA
Methods; 2014 Jan; 65(1):95-104. PubMed ID: 23872324
[TBL] [Abstract][Full Text] [Related]
4. Rapid optimization and prototyping for therapeutic antibody-like molecules.
Xu L; Kohli N; Rennard R; Jiao Y; Razlog M; Zhang K; Baum J; Johnson B; Tang J; Schoeberl B; Fitzgerald J; Nielsen U; Lugovskoy AA
MAbs; 2013; 5(2):237-54. PubMed ID: 23392215
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
[TBL] [Abstract][Full Text] [Related]
6. Advances in Antibody Design.
Tiller KE; Tessier PM
Annu Rev Biomed Eng; 2015; 17():191-216. PubMed ID: 26274600
[TBL] [Abstract][Full Text] [Related]
7. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design.
Von Kreudenstein TS; Escobar-Carbrera E; Lario PI; D'Angelo I; Brault K; Kelly J; Durocher Y; Baardsnes J; Woods RJ; Xie MH; Girod PA; Suits MD; Boulanger MJ; Poon DK; Ng GY; Dixit SB
MAbs; 2013; 5(5):646-54. PubMed ID: 23924797
[TBL] [Abstract][Full Text] [Related]
8. Highly sensitive detection of antibody nonspecific interactions using flow cytometry.
Makowski EK; Wu L; Desai AA; Tessier PM
MAbs; 2021; 13(1):1951426. PubMed ID: 34313552
[TBL] [Abstract][Full Text] [Related]
9. Mabfilin and Fabfilin - New antibody-scaffold fusion formats for multispecific targeting concepts.
Kahl M; Settele F; Knick P; Haupts U; Bosse-Doenecke E
Protein Expr Purif; 2018 Sep; 149():51-65. PubMed ID: 29704557
[TBL] [Abstract][Full Text] [Related]
10. Selection of bispecific antibodies with optimal developability using FcRn‑Ph‑HPLC as an optimized FcRn affinity chromatography method.
Müller T; Tasser C; Tesar M; Fucek I; Schniegler-Mattox U; Koch J; Ellwanger K
MAbs; 2023; 15(1):2245519. PubMed ID: 37599441
[TBL] [Abstract][Full Text] [Related]
11. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
[TBL] [Abstract][Full Text] [Related]
12. Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods.
Makowski EK; Wu L; Gupta P; Tessier PM
MAbs; 2021; 13(1):1895540. PubMed ID: 34313532
[TBL] [Abstract][Full Text] [Related]
13. Rational engineering of antibody therapeutics targeting multiple oncogene pathways.
Fitzgerald J; Lugovskoy A
MAbs; 2011; 3(3):299-309. PubMed ID: 21393992
[TBL] [Abstract][Full Text] [Related]
14. EFab domain substitution as a solution to the light-chain pairing problem of bispecific antibodies.
Cooke HA; Arndt J; Quan C; Shapiro RI; Wen D; Foley S; Vecchi MM; Preyer M
MAbs; 2018; 10(8):1248-1259. PubMed ID: 30215570
[TBL] [Abstract][Full Text] [Related]
15. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
[TBL] [Abstract][Full Text] [Related]
16. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
[TBL] [Abstract][Full Text] [Related]
17. Physicochemical Rules for Identifying Monoclonal Antibodies with Drug-like Specificity.
Zhang Y; Wu L; Gupta P; Desai AA; Smith MD; Rabia LA; Ludwig SD; Tessier PM
Mol Pharm; 2020 Jul; 17(7):2555-2569. PubMed ID: 32453957
[TBL] [Abstract][Full Text] [Related]
18. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G
De Nardis C; Hendriks LJA; Poirier E; Arvinte T; Gros P; Bakker ABH; de Kruif J
J Biol Chem; 2017 Sep; 292(35):14706-14717. PubMed ID: 28655766
[TBL] [Abstract][Full Text] [Related]
19. Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies.
Husain B; Ellerman D
BioDrugs; 2018 Oct; 32(5):441-464. PubMed ID: 30132211
[TBL] [Abstract][Full Text] [Related]
20. Engineering antibodies for therapy.
Presta LG
Curr Pharm Biotechnol; 2002 Sep; 3(3):237-56. PubMed ID: 12164480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
